• 1. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

Professional Introduction to 1-(benzenesulfonyl)-1H-1,3-benzodiazole (CAS No. 15728-43-5) in Modern Chemical and Pharmaceutical Research

1-(benzenesulfonyl)-1H-1,3-benzodiazole, identified by the Chemical Abstracts Service Number (CAS No.) 15728-43-5, is a significant compound in the realm of chemical and pharmaceutical research. This heterocyclic sulfonamide derivative has garnered attention due to its versatile structural framework and potential applications in medicinal chemistry. The benzene ring substituted with a sulfonyl group and linked to a benzodiazole core creates a unique pharmacophore that exhibits intriguing biological activities.

The molecular structure of 1-(benzenesulfonyl)-1H-1,3-benzodiazole consists of a benzodiazole moiety, known for its role in anxiolytic, sedative, and muscle relaxant properties, combined with a benzenesulfonyl group. This sulfonamide functionality enhances the compound's solubility and reactivity, making it a valuable scaffold for drug design. The presence of both electron-withdrawing and electron-donating groups in its structure allows for modulation of its pharmacokinetic and pharmacodynamic profiles, which is crucial for developing novel therapeutic agents.

In recent years, 1-(benzenesulfonyl)-1H-1,3-benzodiazole has been studied for its potential as an intermediate in the synthesis of bioactive molecules. Its benzodiazole core is particularly relevant in the development of treatments for neurological disorders such as epilepsy, anxiety disorders, and sleep disturbances. The sulfonamide group provides additional opportunities for chemical modifications, enabling researchers to explore new derivatives with enhanced efficacy or reduced side effects.

One of the most compelling aspects of 1-(benzenesulfonyl)-1H-1,3-benzodiazole is its role in the development of novel antimicrobial agents. The sulfonamide moiety is well-known for its antibacterial properties, and when combined with the benzodiazole scaffold, it may exhibit synergistic effects against resistant bacterial strains. Recent studies have demonstrated that derivatives of this compound can inhibit bacterial enzymes involved in DNA replication and metabolic pathways, making them promising candidates for further investigation.

The compound's potential as an anti-inflammatory agent has also been explored. Inflammatory processes are mediated by various enzymatic pathways, many of which can be targeted by sulfonamide derivatives. Preliminary research suggests that 1-(benzenesulfonyl)-1H-1,3-benzodiazole may modulate inflammatory responses by inhibiting key enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX). These findings highlight its potential as a lead compound for developing anti-inflammatory drugs with improved selectivity and reduced toxicity.

Another area where 1-(benzenesulfonyl)-1H-1,3-benzodiazole shows promise is in the treatment of cancer. The benzodiazole core has been identified as a potential chemopreventive agent due to its ability to induce apoptosis in cancer cells while sparing healthy cells. The sulfonamide group further enhances this property by facilitating cellular uptake and increasing bioavailability. Current research is focused on synthesizing analogs of this compound that can selectively target tumor cells without causing systemic toxicity.

The synthesis of 1-(benzenesulfonyl)-1H-1,3-benzodiazole involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic techniques such as palladium-catalyzed cross-coupling reactions have been employed to introduce the sulfonyl group onto the benzodiazole core efficiently. These methods not only improve the scalability of production but also allow for the introduction of diverse substituents at strategic positions within the molecule.

The pharmacological evaluation of 1-(benzenesulfonyl)-1H-1,3-benzodiazole has revealed several interesting properties. In vitro studies have shown that it can interact with various biological targets, including receptors and enzymes involved in neurotransmission and inflammation. Additionally, animal models have demonstrated its potential as an anxiolytic agent with fewer side effects compared to traditional benzodiazepines. These findings are encouraging and warrant further clinical investigations to validate its therapeutic efficacy.

The future direction of research on 1-(benzenesulfonyl)-1H-1,3-benzodiazole includes exploring its role in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The benzodiazole core has been shown to modulate cholinergic systems, which are implicated in these conditions. By combining this with the sulfonamide group's ability to cross the blood-brain barrier efficiently, researchers aim to develop compounds that can slow down disease progression without causing cognitive impairment.

In conclusion, 15728-43-5 represents a promising scaffold for drug discovery due to its unique structural features and diverse biological activities. Its combination of a benzodiazole core with a benzenesulfonyl group provides multiple opportunities for chemical modification and therapeutic application. As research continues to uncover new biological functions and synthetic strategies, 15728-43-5 is poised to play a significant role in the development of next-generation pharmaceuticals.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)